Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$4.16 USD
+0.12 (2.97%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $4.16 0.00 (0.00%) 4:40 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADPT 4.16 +0.12(2.97%)
Will ADPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
Other News for ADPT
3 Precision Medicine Stocks Tailoring Treatments
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies announces data on MRD assessment with clonoSEQ
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference